These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16839858)

  • 1. Study of hepatotoxicity of naltrexone in the treatment of alcoholism.
    Yen MH; Ko HC; Tang FI; Lu RB; Hong JS
    Alcohol; 2006 Feb; 38(2):117-20. PubMed ID: 16839858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.
    Vagenas P; Di Paola A; Herme M; Lincoln T; Skiest DJ; Altice FL; Springer SA
    J Subst Abuse Treat; 2014 Jul; 47(1):35-40. PubMed ID: 24674234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone.
    Tetrault JM; Tate JP; McGinnis KA; Goulet JL; Sullivan LE; Bryant K; Justice AC; Fiellin DA;
    Alcohol Clin Exp Res; 2012 Feb; 36(2):318-24. PubMed ID: 21797892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics.
    Lucey MR; Silverman BL; Illeperuma A; O'Brien CP
    Alcohol Clin Exp Res; 2008 Mar; 32(3):498-504. PubMed ID: 18241321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection.
    Mitchell MC; Memisoglu A; Silverman BL
    J Stud Alcohol Drugs; 2012 Nov; 73(6):991-7. PubMed ID: 23036218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained-release naltrexone for alcoholism treatment: a preliminary study.
    Kranzler HR; Modesto-Lowe V; Nuwayser ES
    Alcohol Clin Exp Res; 1998 Aug; 22(5):1074-9. PubMed ID: 9726277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of hepatotoxicity with naltrexone treatment.
    Sax DS; Kornetsky C; Kim A
    J Clin Pharmacol; 1994 Sep; 34(9):898-901. PubMed ID: 7983232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in transaminases over the course of a 12-week, double-blind nalmefene trial in a 38-year-old female subject.
    Salvato FR; Mason BJ
    Alcohol Clin Exp Res; 1994 Oct; 18(5):1187-9. PubMed ID: 7847604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems.
    Goonoo N; Bhaw-Luximon A; Ujoodha R; Jhugroo A; Hulse GK; Jhurry D
    J Control Release; 2014 Jun; 183():154-66. PubMed ID: 24704710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of cyanamide and disulfiram in effects on liver function.
    Tamai H; Yokoyama A; Okuyama K; Takahashi H; Maruyama K; Suzuki Y; Ishii H
    Alcohol Clin Exp Res; 2000 Apr; 24(4 Suppl):97S-99S. PubMed ID: 10803789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatients.
    Kim SW; Grant JE; Yoon G; Williams KA; Remmel RP
    Clin Neuropharmacol; 2006; 29(2):77-9. PubMed ID: 16614539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
    Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
    Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of the efficacy of naltrexone in alcoholism by the determination of serum carbohydrate-deficient transferrin].
    Martinez Ruiz M; Llobell Segui G; Peralba Vaño JL; Toral Revuelta JR
    An Med Interna; 1995 Dec; 12(12):589-92. PubMed ID: 8679801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature.
    Brewer C; Wong VS
    Addict Biol; 2004 Mar; 9(1):81-7. PubMed ID: 15203443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials.
    O'Malley SS; Rounsaville BJ; Farren C; Namkoong K; Wu R; Robinson J; O'Connor PG
    Arch Intern Med; 2003 Jul; 163(14):1695-704. PubMed ID: 12885685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of diphenyl-dimethyl-dicarboxylate plus garlic oil in patients with chronic hepatitis.
    Lee MH; Kim YM; Kim SG
    Int J Clin Pharmacol Ther; 2012 Nov; 50(11):778-86. PubMed ID: 22943930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naltrexone-induced nausea in patients treated for alcohol dependence: clinical predictors and evidence for opioid-mediated effects.
    O'Malley SS; Krishnan-Sarin S; Farren C; O'Connor PG
    J Clin Psychopharmacol; 2000 Feb; 20(1):69-76. PubMed ID: 10653211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
    Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
    Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case report of naltrexone for alcoholism in a liver transplant recipient: side effects and safety.
    Weinrieb RM; O'Brien CP
    Am J Addict; 2004; 13(5):495-7. PubMed ID: 15764427
    [No Abstract]   [Full Text] [Related]  

  • 20. [Alcohol dependence treatment with naltrexone: safety assessment. Observation study group of alcoholic dependence].
    Ochoa Mangado E; Arias Horcajadas F; Torres Hernández MA
    Actas Esp Psiquiatr; 2000; 28(3):161-8. PubMed ID: 11000698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.